At CSL we are driven by our promise, to save lives and protect the health of people.

Ensuring we can continue to develop and deliver life-saving and life-enhancing therapies to patients around the world is our corporate responsibility.

22,220 Employees around the world
35+ Countries Of operations around the world
$7.9+ Billion In annual revenue
CSL global serious complaint reports received with no violations of law or increased risk to our organisation.

US$39.5 Million in global community investment.

57 374 489

US$7.5 Billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.*

22,220 employees up 13%

56% Women

44% Men

75% employee engagement* score

is three points above IBM Smarter Workforce Employee Engagement Norm.

17% Medical Treatment*

0 Fatalities*

26% Lost Time*

53% Days Lost*

90 authored or co-authored articles published in high-quality peer-reviewed journals.

25 product registrations or new indications in numerous countries.

99.3% of plasma donors are willing to donate again.

374 regulatory inspections of manufacturing facilities with no impact to licences or operations.*

489 quality audits of our suppliers.*

96.8% of plasma donors are willing to refer a friend to a centre.

5 voluntary safety-related recalls initiated.*

96.8% of plasma donors are willing to refer a friend to a centre.

99.3% of plasma donors are willing to donate again.

US$702 Million in research and development.*

90

25

US$39.5 Million in global community investment.

US$7.5 Billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.*

0 breaches of product marketing and promotional activities by the US FDA, EMA or Medicines Australia.*†

96.8% of plasma donors are willing to refer a friend to a centre.

5 voluntary safety-related recalls initiated.*

57

5% breaches of product marketing and promotional activities by the US FDA, EMA or Medicines Australia.*†

57 374 489

US$7.5 Billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.*

* 2017/18 data received independent external, limited assurance.

† EMA = European Medicines Agency, FDA = Food and Drug Administration